Chimeric antigen receptor T cells and T cell-redirecting bispecific antibody therapies are changing the landscape of myeloma therapy. Two studies investigate the genetic and epigenetic resistance mechanisms that lead to relapse in patients receiving T cell-engaging therapies targeting B cell maturation antigen (BCMA) and GPRC5D.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Munshi, N. C. et al. N. Engl. J. Med. 384, 705–716 (2021).
Berdeja, J. G. et al. Lancet 398, 314–324 (2021).
San-Miguel, J. et al. N. Engl. J. Med. 389, 335–347 (2023).
Moreau, P. et al. N. Engl. J. Med. 387, 495–505 (2022).
Rodriguez-Otero, P. et al. N. Engl. J. Med. 388, 1002–1014 (2023).
Mailankody, S. et al. N. Engl. J. Med. 387, 1196–1206 (2022).
Chari, A. et al. N. Engl. J. Med. 387, 2232–2244 (2022).
Holstein, S. A., Grant, S. J. & Wildes, T. M. J. Clin. Oncol. https://doi.org/10.1200/JCO.23.00512 (2023).
Lee, H. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02491-5 (2023).
Derrien, J. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00625-9 (2023).
Bird, S. & Pawlyn, C. Blood 142, 131–140 (2023).
Truger, M. S. et al. Blood Adv. 5, 3794–3798 (2021).
Da Vià, M. C. et al. Nat. Med. 27, 616–619 (2021).
Samur, M. K. et al. Nat. Commun. 12, 868 (2021).
Friedrich, M. J. et al. Cancer Cell 41, 711–725.e6 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
B.P. reports consultancy fees from BMS, GSK, Janssen, Sanofi and Takeda; research funding from BMS, GSK, Roche and Sanofi; and honoraria from Adaptive, Amgen, Becton Dickinson, BMS-Celgene, GSK, Janssen, Sanofi and Roche. J.F.S.-M. reports consultancy fees from Abbvie, Amgen, BMS, Celgene, Roche, GSK, Janssen, Karyopharm, Merck, Novartis, Sanofi and Takeda.
Rights and permissions
About this article
Cite this article
Paiva, B., San-Miguel, J.F. Myeloma evades T cell-engaging therapies. Nat Cancer 4, 1534–1535 (2023). https://doi.org/10.1038/s43018-023-00637-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00637-5
